Pharmacokinetics and biotransformation of mirtazapine in human volunteers

Clinical Drug Investigation

Volumn 15, Issue 1, 1998, Pages 45-55

  Delbressine, L P C ^a   Moonen, M E G ^a   Kaspersen, F M ^a   Wagenaars, G N ^a   Jacobs, P L ^a   Timmer, C J ^a   Paanakker, J E ^a   Van Hal, H J M ^a   Voortman, G ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONIDE; MIRTAZAPINE; TETRACYCLIC ANTIDEPRESSANT AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; ENANTIOMER; FECES; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RACEMIC MIXTURE; URINE;

EID: 0031930087     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199815010-00006     Document Type: Article

References (15)

1. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996; 5 (5): 389-402
2. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacology 1995; 10 Suppl. 4: 19-23
3. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Hum Psychopharmacol 1995; 10 Suppl. 2: S83-S96
4. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron tablets. Hum Psychopharmacol 1995; 10 Suppl. 2: S97-S106
5. Delbressine LPC, Vos RME. The clinical relevance of preclinical data: mirtazapine, a model compound. J Clin Psychopharmacol 1997; 17 Suppl. 1: 29-33
6. Lohmann A, Dingier E, Ernst M. Validation of the gas-chromatographic assay for the determination of mirtazapine and its demethyl metabolite in human plasma. 1995. Data on file, Organon N.V., Oss, The Netherlands
7. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation. V: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992; 81: 309-12
8. 14C. J Label Compounds Radiopharm 1989; 27: 1055-68
9. van Boeckel CAA, Delbressine LPC, Kaspersen FM. The synthesis of glucuronides derived from the antidepressant drugs mianserin and Org 3770. Recl Trav Chim Pays-Bas 1985; 104: 259-65
10. Jacobs PL, Delbressine LPC, Kaspersen FM, et al. A mass spectrometric approach to the identification of conjugated drug metabolites. Biomed Environ Mass Spectrometry 1987; 14: 689-97
11. Dahl M-L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 1997; 13: 37-46
12. 2 receptors. Eur Neuropsychopharmacol 1996; 6 Suppl. 3: 52-3
13. Graaf JS de, Delbressine LPC. Contributions of the enantiomers of Org 3770 and its demethyl metabolite to its neuropharmacological profile in rats [abstracts S1, sn]. Trends Drug Res 1989; 69
14. 13C-labelled mirtazapine. In: Allen J, Voges R, editors. Synthesis and applications of isotopically labelled compounds. 1994: 827-30
15. Sandker GW, Vos RME, Delbressine LPC, et al. Metabolism of three pharmacologically active drugs in isolated human and rat hepatocytes: analysis of interspecies variability and comparison with metabolism in vivo. Xenobiotica 1994; 24: 143-55